Risk vs. Benefit Lessons from the ORAL Surveillance Study
Jan 27, 2022
Latest ACR News
In an editorial in the current edition of the NEJM, Dr. Jasvinder Singh comments on the Oral Surveillance trial (Ytterberg et al.), a 4-year randomized, open-label, noninferiority, postauthorization, safety end-point trial, in high risk active rheumatoid arthritis patients over age 50 years.Read Article
Making Better Posters: Dr. David Liew Dr. David Liew describes how some presenters are working to make their posters better design-wise to improve their presentation at the 2019 ACR/ARP annual meeting in Atlanta.
Romosozumab and Patients with Chronic Kidney Disease: Dr. Arthur Lau Dr. Lau discusses abstract #2730 presented at the 2019 ACR/ARP annual meeting in Atlanta.
SJIA-associated ILD: Dr. Jonathan Hausmann Dr. Hausmann describes a new inflammatory lung disease at the 2019 ACR/ARP annual meeting in Atlanta.
Lupus Pearls: Dr. Kathryn Dao Dr. Dao reviews several lupus pearls presented by Dr. Michelle Petri at the 2019 ACR/ARP Annual Meeting in Atlanta.
Panel Presentation: Gout Drs. Jack Cush, Nicola Dalbeth, Ken Saag, and Robert Keenan discuss key presentations related to gout presented at the 2019 ACR/ARP Annual Meeting in Atlanta.
Myosin Regulation May Contribute to Anti-TNF Therapy Response: Dr. Elaine Husni Dr. Husni highlights abstract #1769 as presented at the 2019 ACR/ARP Annual Meeting in Atlanta.
Inflammatory Arthritis Persists After Immunotherapy Cessation: Dr. David Liew Dr. Liew discusses abstract #1808 Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Persists After Immunotherapy Cessation presented at the 2019 ACR/ARP Annual Meeting in Atlanta.
Studies on the Changing Face of RA: Dr. Janet Pope Dr. Pope discusses abstract #171, #172 and #841 as presented at the 2019 ACR/ARP Annual Meeting in Atlanta.
Panel Presentation: Rheumatoid Arthritis Drs. Jack Cush, Arthur Kavanaugh and Jonathan Kay discuss several rheumatoid arthritis studies presented at the 2019 ACR/ARP Annual Meeting in Atlanta. Abstracts discussed include abstract #1342, #1350, #1160, and more.
Drug Levels Associated with Lupus Flares: Dr. Janet Pope: Dr. Pope discusses abstract #2567 Prospective Evaluation of American Academy of Ophthalmology Low Dose Hydroxychloroquine Recommendation in Stable Lupus Nephritis with High-Risk Retinopathy: Lipid Profile and Flare Rates presented at the 2019 ACR/ARP annual meeting in Atlanta.
Safety of Methotrexate (The CIRT Trial): Dr. Jack Cush Dr. Cush discusses abstract #1890 on the CIRT trial as presented at the 2019 ACR/ARP annual meeting in Atlanta.
Dr. Dao talks with Dr. Gwenesta Melton about Women in Rheumatology Dr. Dao interviews Dr. Melton about Women in Rheumatology
Social Media Professionalism: Dr. Michael Putman and Dr. Jilaine Bolek Berquist Dr. Michael Putman talks with Dr. Jilaine Bolek Berquist about her talk on tweets and trolls in social media at the 2019 ACR/ARP annual meeting in Atlanta.
Domain Strategy and Treatment in Psoriatic Arthritis: Dr. Elaine Husni Dr. Elaine Husni reviews her talk on domain strategies in PsA at the 2019 ACR/ARP annual meeting in Atlanta.
